OBI Pharma (4174) - Net Assets
Based on the latest financial reports, OBI Pharma (4174) has net assets worth NT$3.08 Billion TWD (≈ $97.05 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$3.83 Billion ≈ $120.64 Million USD) and total liabilities (NT$748.70 Million ≈ $23.59 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 4174 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$3.08 Billion |
| % of Total Assets | 80.45% |
| Annual Growth Rate | 18.89% |
| 5-Year Change | -0.36% |
| 10-Year Change | -32.9% |
| Growth Volatility | 111.67 |
OBI Pharma - Net Assets Trend (2011–2024)
This chart illustrates how OBI Pharma's net assets have evolved over time, based on quarterly financial data. Also explore how large is OBI Pharma's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for OBI Pharma (2011–2024)
The table below shows the annual net assets of OBI Pharma from 2011 to 2024. For live valuation and market cap data, see OBI Pharma market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$4.82 Billion ≈ $151.87 Million |
-2.69% |
| 2023-12-31 | NT$4.95 Billion ≈ $156.06 Million |
-19.27% |
| 2022-12-31 | NT$6.14 Billion ≈ $193.32 Million |
+58.52% |
| 2021-12-31 | NT$3.87 Billion ≈ $121.95 Million |
-19.99% |
| 2020-12-31 | NT$4.84 Billion ≈ $152.42 Million |
-7.04% |
| 2019-12-31 | NT$5.20 Billion ≈ $163.96 Million |
+16.33% |
| 2018-12-31 | NT$4.47 Billion ≈ $140.94 Million |
-11.60% |
| 2017-12-31 | NT$5.06 Billion ≈ $159.43 Million |
-17.86% |
| 2016-12-31 | NT$6.16 Billion ≈ $194.10 Million |
-14.24% |
| 2015-12-31 | NT$7.18 Billion ≈ $226.34 Million |
+397.55% |
| 2014-12-31 | NT$1.44 Billion ≈ $45.49 Million |
-25.16% |
| 2013-12-31 | NT$1.93 Billion ≈ $60.78 Million |
+132.50% |
| 2012-12-31 | NT$829.77 Million ≈ $26.14 Million |
+63.20% |
| 2011-12-31 | NT$508.44 Million ≈ $16.02 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to OBI Pharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 737809300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$11.69 Billion | 306.55% |
| Total Equity | NT$3.81 Billion | 100.00% |
OBI Pharma Competitors by Market Cap
The table below lists competitors of OBI Pharma ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chenghe Acquisition III Co. Class A Ordinary Share
NASDAQ:CHEC
|
$131.95 Million |
|
DASAN Networks Inc
KQ:039560
|
$131.97 Million |
|
Dala Energi AB
ST:DE
|
$132.00 Million |
|
IKIO Lighting Limited
NSE:IKIO
|
$132.01 Million |
|
SHL Consolidated Bhd
KLSE:6017
|
$131.91 Million |
|
Graphene Manufacturing Group Ltd
V:GMG
|
$131.90 Million |
|
Bisi International Tbk
JK:BISI
|
$131.84 Million |
|
Igarashi Motors India Limited
NSE:IGARASHI
|
$131.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OBI Pharma's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,806,731,000 to 3,814,674,000, a change of 7,943,000 (0.2%).
- Net loss of 2,310,026,000 reduced equity.
- New share issuances of 2,163,200,000 increased equity.
- Other comprehensive income decreased equity by 2,042,169,000.
- Other factors increased equity by 2,196,938,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-2.31 Billion | -60.56% |
| Share Issuances | NT$2.16 Billion | +56.71% |
| Other Comprehensive Income | NT$-2.04 Billion | -53.53% |
| Other Changes | NT$2.20 Billion | +57.59% |
| Total Change | NT$- | 0.21% |
Book Value vs Market Value Analysis
This analysis compares OBI Pharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.10x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.93x to 1.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | NT$5.37 | NT$31.85 | x |
| 2012-12-31 | NT$6.23 | NT$31.85 | x |
| 2013-12-31 | NT$13.43 | NT$31.85 | x |
| 2014-12-31 | NT$9.47 | NT$31.85 | x |
| 2015-12-31 | NT$42.39 | NT$31.85 | x |
| 2016-12-31 | NT$35.46 | NT$31.85 | x |
| 2017-12-31 | NT$29.01 | NT$31.85 | x |
| 2018-12-31 | NT$24.86 | NT$31.85 | x |
| 2019-12-31 | NT$26.35 | NT$31.85 | x |
| 2020-12-31 | NT$21.08 | NT$31.85 | x |
| 2021-12-31 | NT$13.51 | NT$31.85 | x |
| 2022-12-31 | NT$20.85 | NT$31.85 | x |
| 2023-12-31 | NT$16.62 | NT$31.85 | x |
| 2024-12-31 | NT$29.01 | NT$31.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OBI Pharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -60.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3685.55%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.48x
- Recent ROE (-60.56%) is below the historical average (-33.77%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -25.09% | 0.00% | 0.00x | 1.03x | NT$-178.43 Million |
| 2012 | -30.76% | 0.00% | 0.00x | 1.05x | NT$-338.25 Million |
| 2013 | -22.73% | 0.00% | 0.00x | 1.02x | NT$-631.50 Million |
| 2014 | -46.20% | 0.00% | 0.00x | 1.03x | NT$-811.39 Million |
| 2015 | -13.10% | 0.00% | 0.00x | 1.02x | NT$-1.66 Billion |
| 2016 | -18.02% | -1201.15% | 0.01x | 1.03x | NT$-1.73 Billion |
| 2017 | -27.26% | -366871.28% | 0.00x | 1.03x | NT$-1.89 Billion |
| 2018 | -28.12% | -9162.92% | 0.00x | 1.08x | NT$-1.66 Billion |
| 2019 | -28.20% | -165090.60% | 0.00x | 1.11x | NT$-1.95 Billion |
| 2020 | -35.23% | -1057.52% | 0.03x | 1.26x | NT$-1.91 Billion |
| 2021 | -63.25% | -9151.34% | 0.00x | 1.65x | NT$-1.99 Billion |
| 2022 | -41.00% | -40316.79% | 0.00x | 1.43x | NT$-2.36 Billion |
| 2023 | -33.26% | -3046.91% | 0.01x | 1.47x | NT$-1.65 Billion |
| 2024 | -60.56% | -3685.55% | 0.01x | 1.48x | NT$-2.69 Billion |
Industry Comparison
This section compares OBI Pharma's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,782,670,400
- Average return on equity (ROE) among peers: 2.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OBI Pharma (4174) | NT$3.08 Billion | -25.09% | 0.24x | $131.94 Million |
| Apex Biotechnology Corp (1733) | $1.35 Billion | 29.84% | 0.15x | $89.90 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $3.42 Billion | 0.26% | 0.72x | $188.76 Million |
| Panion & BF Biotech Inc (1760) | $2.01 Billion | 9.08% | 0.54x | $184.23 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $3.36 Billion | 1.58% | 0.42x | $68.46 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $996.24 Million | 6.00% | 0.56x | $99.61 Million |
| Level Biotechnology (3118) | $522.28 Million | 13.08% | 0.40x | $34.35 Million |
| GenMont Biotech Inc (3164) | $290.14 Million | -2.84% | 0.08x | $47.96 Million |
| Medigen Biotechnology (3176) | $3.54 Billion | -16.06% | 0.36x | $144.62 Million |
| Sagittarius Life Science (3205) | $965.47 Million | -11.83% | 0.10x | $119.60 Million |
| Genovate Biotechnology Co Ltd (4130) | $1.38 Billion | 0.03% | 0.10x | $98.37 Million |
About OBI Pharma
OBI Pharma, Inc., a clinical stage oncology company, research and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company's pipeline products include Adagloxad simolenin which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424 which has co… Read more